关键字不能为空!

Enter

Home » News » News

Musculoskeletal Tumor & Dermatology | Prof. Guo Wei’s Team and Prof. Zhang Jianzhong's Team at PKUPH Win Chinese Medical Science and Technology Awards
骨肿瘤科郭卫教授、皮肤科张建中教授团队分获中华医学科技奖

2023-11-30

On November 26, 2023, the Chinese Medical Science and Technology Awards ceremony was held by Chinese Medical Association (CMA) in Beijing, where the winners of the 2022 awards were honored. The CMA, established in 1915, is a non-profit registered academic and commonweal corporate body voluntarily formed by Chinese medical science and technology professionals, and an important social force in the development of medical science and technology in China.

Professor Guo Wei and Professor Zhang Jianzhong from Peking University People's Hospital (PKUPH) led teams that were awarded the first and second prizes, respectively, at the ceremony for their projects.


Professor Guo Wei's team was recognized for their project "Key Technologies and Clinical Applications of Repairing and Reconstructing Large Bone Joint Defects after Bone Tumor Resection," which significantly improves the prognosis and postoperative function of patients with malignant bone tumors in China. They solved the global challenge of repairing and reconstructing large bone joint defects after bone tumor resection through innovative concepts and patent transformation, using key technologies such as composite design and additive manufacturing. Their universal pelvic bone system, with multiple patents in the United States, Europe, and China, has been successfully applied in clinical settings. It has become internationally recognized as the most effective solution for the largest cohort of pelvic ring tumor resections and functional reconstructions. The main contributors to the project were Guo Wei, Tang Xiaodong, Ji Tao, Yang Yi, Liang Haijie, Wei Ran, Yang Rongli, Yan Taiqiang, Li Dasen, Qu Huayi, Du Zhiye, Zang Jie.




Professor Guo Wei (third from the left) receiving the award.


Professor Zhang Jianzhong's team spent over a decade to successfully develop Benvitimod (also known as Tapinarof). This medicine marks another groundbreaking in psoriasis treatment since the introduction of Vitamin D3 derivatives in 1980. Benvitimod, approved by China’s National Medical Products Administration (NMPA) in May 2019, is a non-hormonal small molecule drug and an aryl hydrocarbon receptor modulator. It has relieved pain for nearly 200,000 psoriasis patients and was launched in the United States in 2022. The team's dedication and groundbreaking research have significantly advanced the field of dermatology and topical drug development. The main contributors to the project were Zhang Jianzhong, Chen Genghui, Cai Lin, Li Jianxiong, Fang Yi, Zhao Yan, Lu Qianjin, Sun Qiuning, Zheng Min, and Ma Xiaolei.




Professor Zhang Jianzhong (fifth from the right) receiving the award.


These achievements reflected the dedication and excellence of Chinese medical researchers in advancing healthcare and addressing critical medical challenges, both nationally and globally.